

## Special Issue

# The Challenges and Therapeutic Prospects in Eye Disease

### Message from the Guest Editor

In the last decade we have gained a deeper understanding of the underlying pathogenesis of various ocular disease, which has resulted in the development of novel effective targeted therapies such as teprotumumab for the treatment of active thyroid eye disease. This Special Issues of *Journal of Personalized Medicine* aims to update the current evidence and collect the latest findings on various ocular disease. Particular attention will be paid to original research articles, case reports, and state-of-the-art reviews to explore how to *overcome* the *challenges* and navigate the emerging therapeutic landscape.


### Guest Editor

Dr. Tsai Chieh-Chih

1. Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
2. School of Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan

### Deadline for manuscript submissions

closed (25 April 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/104563](https://mdpi.com/si/104563)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).